Posted on

Rocket Lab Fully Funds Iridium Acquisition, Including Completion of $1.94 Billion ATM

LONG BEACH, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today announced it has successfully completed several critical milestones to fully finance its pending acquisition of Iridium Communications Inc. (“Iridium” and such pending transaction, the “Iridium Acquisition”).

By sf-admin
Posted on

Rocket Lab Fully Funds Iridium Acquisition, Including Completion of $1.94 Billion ATM

LONG BEACH, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today announced it has successfully completed several critical milestones to fully finance its pending acquisition of Iridium Communications Inc. (“Iridium” and such pending transaction, the “Iridium Acquisition”).

By sf-admin
Posted on

TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026

Basel, September 15, 2026 – TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company pioneering therapies targeting non-oncogene addiction in cancer, today announced the completion of its Phase I study of monotherapy TT125-802 (NCT06403436) and the presentation of final clinical data from the study at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. The data highlights TT125-802’s confirmed clinical activity as monotherapy in drug-resistant NSCLC and supports CBP/p300 inhibition as a novel therapeutic strategy to address transcriptional drug resistance in solid tumors.

By sf-admin
Posted on

TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026

Basel, September 15, 2026 – TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company pioneering therapies targeting non-oncogene addiction in cancer, today announced the completion of its Phase I study of monotherapy TT125-802 (NCT06403436) and the presentation of final clinical data from the study at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. The data highlights TT125-802’s confirmed clinical activity as monotherapy in drug-resistant NSCLC and supports CBP/p300 inhibition as a novel therapeutic strategy to address transcriptional drug resistance in solid tumors.

By sf-admin
Posted on

Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program

VIENNA, September 15, 2026 — Aitiologic, a precision medicine company developing tissue-resolved liquid biopsy solutions, today announced the close of a significantly oversubscribed €6.4 million (approximately $7.4 million) seed financing, co-led by Heal Capital and Ananda Impact Ventures. The financing will support ongoing large-scale validation and regulated product development of Aitios®, the company’s multi-modal cell-free DNA (cfDNA) platform, initially for first-trimester preeclampsia risk stratification. Dr. Gordon Sanghera CBE FRS, an established pioneer in molecular diagnostics, participated in the seed round as an investor and will join the company’s advisory board. To further advance the clinical translation of the preeclampsia lead program, Dr. Rebecca Ertl has been appointed Chief Medical Officer.

By sf-admin
Posted on

LearnEnglishAbc.com Expands Worldwide ESL Learning Platform With HOPE AI Tutor, Free Plan, and Read-Aloud Library

The platform combines structured English lessons, 164 graded books with narration, songs, grammar, and AI conversation practice to help learners build confidence in English. 

The platform combines structured English lessons, 164 graded books with narration, songs, grammar, and AI conversation practice to help learners build confidence in English.

By sf-admin